The short answer
Once a medical device company has revenue, total marketing spend typically runs 5 to 13 percent of revenue, and the right number inside that band depends on stage. Pre-clearance companies budget bottoms-up, often 15,000 to 45,000 dollars per month. Launch-stage companies invest most heavily, 10 to 20 percent of revenue, and split spend almost evenly between digital and conferences. Scale-stage companies settle to 4 to 8 percent and shift the mix toward digital and sales enablement.
For external context, the Gartner 2025 CMO Spend Survey put the cross-industry average at 7.7 percent of revenue, and the Deloitte, Duke, and AMA CMO Survey reported 9.4 percent. Healthcare sat below both averages. The first thing to cut is underperforming conferences, where two or three events usually drive about 80 percent of event-sourced pipeline.
The percentages and ranges on this page are modeled benchmarks from the budget framework Buzzbox Media publishes and uses with medtech clients. They are not survey results, and we do not claim to have surveyed medical device companies. Where this page reports a third-party figure, such as a published percentage of revenue or a documented shift in buyer behavior, that number is cited inline to a named source. You can reproduce the modeled numbers yourself with our medical device marketing budget calculator or read the full method in our medical device marketing budget template.
How to read these benchmarks
A marketing budget benchmark is only useful if it is anchored to a company stage. A pre-clearance startup and an established manufacturer with a billion dollars in revenue both ask the same question, "how much should we spend on marketing," but the answer for one would bankrupt the other. We use three stages because they map to how device companies actually budget:
- Pre-clearance: the 12 to 24 months before, or right around, FDA clearance or CE marking. Little or no commercial revenue, so spend is set bottoms-up, not as a percentage.
- Launch: the first one to two years on the market. The highest marketing intensity of any stage, because awareness has to be built from zero.
- Scale: an established commercial business defending and growing share. The marketing percentage drops, but the absolute dollar figure is the largest of the three.
The external benchmarks confirm the shape. Gartner found that marketing budgets across industries held at 7.7 percent of revenue in 2025, and that half of CMOs reported budgets of 6 percent or less, which tells you the median company sits below the headline average. The Deloitte, Duke, and AMA CMO Survey put the figure higher at 9.4 percent, reflecting a broader mix of company sizes. Healthcare came in below both averages in each survey, which is why our scale-stage band tops out at 8 percent rather than the cross-industry 9 to 10 percent.
Benchmark 1: Total marketing spend by company stage
This table is the headline benchmark: what a medical device company spends in total, by stage, expressed both as a percentage of revenue and as a monthly dollar range for early-stage companies that do not yet budget on a percentage basis.
| Company stage | Spend as % of revenue | Typical monthly spend | What the budget is buying |
|---|---|---|---|
| Pre-clearance | 15 to 25% (of any early revenue); usually set bottoms-up | $15K to $45K | Awareness, clinical narrative, regulatory-ready content, 2 to 4 key conferences |
| Launch | 10 to 20% | $35K to $120K | Demand generation, conference presence, sales enablement, launch campaigns |
| Scale | 4 to 8% | $120K and up | Share defense, competitive positioning, portfolio marketing, retention |
Swipe the table sideways to see every column.
Percentage ranges and monthly figures: modeled from the Buzzbox Media budget framework. Cross-industry reference points: Gartner 2025 CMO Spend Survey (7.7% of revenue average; half of CMOs at 6% or less) and the Deloitte, Duke, and AMA CMO Survey 2025 (9.4% of revenue), both cited in full below.
The monthly dollar ranges matter most pre-revenue, where a percentage of revenue is meaningless. Three variables move the number more than anything else: funding stage, FDA pathway, and sales motion. A 510(k) clearance front-loads regulatory and clinical content, while a PMA pathway front-loads key opinion leader relationships and society engagement. A direct sales force needs more sales enablement spend than a distributor model. Run your own specifics through the budget calculator to see how those variables shift the figure.
Benchmark 2: Channel allocation by stage
Total spend is the easy question. The allocation inside that total is where most budgets go wrong. The table below shows the modeled channel mix for each stage, as a percentage of the total marketing budget. Every row sums to 100 percent.
| Channel | Pre-clearance | Launch | Scale |
|---|---|---|---|
| Digital marketing (SEO, PPC, social) | 30% | 25% | 30% |
| Conferences & trade shows | 20% | 25% | 20% |
| Content & thought leadership | 20% | 15% | 18% |
| Branding & creative | 12% | 10% | 8% |
| Video production | 8% | 10% | 8% |
| Sales enablement | 5% | 10% | 8% |
| PR & communications | 5% | 5% | 8% |
| Total | 100% | 100% | 100% |
Swipe the table sideways to see every column.
Allocation percentages: modeled from the Buzzbox Media budget framework, matching the stage-based mix in our budget calculator. Behavioral context for the digital weighting is cited below.
Two patterns are worth calling out. First, digital is the single largest line in every stage, never below 25 percent. That is not a preference, it is a response to where the buyer is. McKinsey found that up to 60 percent of healthcare professionals prefer digital or remote engagement when researching unfamiliar technologies, requesting proposals, and purchasing. A budget that treats digital as a minority channel is budgeting for a buyer who no longer exists.
Second, conferences peak at launch and ease off at scale. Launch budgets weight conferences as heavily as digital because that is where a new device earns its first hands-on demos and word-of-mouth. By the scale stage, the buyer journey has moved online and the conference line gives ground to digital and PR. This mirrors the industry-wide shift: the MM+M Healthcare Marketers Trend Report 2025 found that use of professional meetings and conferences fell from 74 percent to 59 percent of marketers year over year, while more than 72 percent of healthcare ad budgets now go to digital channels.
If you only take one thing from the allocation table: a medical device company that puts less than a quarter of its budget into digital is almost certainly invisible during the research phase, when surgeons, biomedical engineers, and procurement officers form their shortlist. Building organic search authority takes 12 to 18 months, so the cost of underfunding it is paid a year later, not next quarter.
Benchmark 3: What to cut first
Every budget eventually has to absorb a cut. The order matters more than the amount. The table below ranks where to take budget out, and what to protect, based on the pattern we see most often across medtech programs.
| Cut order | Line item | Why it goes first (or last) |
|---|---|---|
| Cut 1st | Underperforming conferences | Two or three events typically drive about 80% of event-sourced pipeline; the rest spend budget with little tracked return. |
| Cut 2nd | Untracked paid media | Any paid spend not tied to a measured conversion is the easiest dollar to lose without losing pipeline. |
| Cut 3rd | Brand and creative refreshes | Important, but deferrable a quarter or two without immediate pipeline impact. |
| Protect | SEO and evergreen content | Compounds over 12 to 18 months and stops compounding the moment it is defunded. |
| Protect | Sales enablement | Directly affects close rates on pipeline you already paid to generate. |
Swipe the table sideways to see every column.
Cut order: modeled from the Buzzbox Media budget framework and the budget-mistake patterns documented in our budget template. The 80 percent event-sourced pipeline concentration is a planning heuristic from that framework, not a third-party survey statistic.
How these benchmarks fit a real plan
Benchmarks set the guardrails. They do not write the plan. A useful budget starts top-down (revenue target times the stage percentage) and is then validated bottoms-up against the actual cost of the campaigns, events, and content on the roadmap. Where bottoms-up exceeds top-down, the cut order above tells you what to trim. For the full step-by-step build, including monthly phasing and ROI tracking, see the medical device marketing budget template.
If you want a partner to pressure-test the allocation against your category, stage, and competitive set, that is the core of what a specialized medical device marketing agency does. The point of publishing these benchmarks openly is that the framework should stand on its own, whether or not you ever work with us.